CD33 and acute myeloid leukemia: While we demonstrated the binding superiority of M2T-CD33 induced IgGs over gemtuzumab and lintuzumab, future head-to-head studies are required to fully demonstrate superior anti-leukemic activity of M2T-CD33 in AML models.